| Primary information |
|---|
| sequence ID | Seq_1912 |
| Peptide sequence | EPGSPGENGAPGQMGPRG |
| CancerPDF_ID | CancerPDF_ID4773, CancerPDF_ID10820, |
| PMID | 24982608,21805675 |
| Protein Name | Collagen alpha-1(I) chain,Collagen alpha-1(I) chain |
| UniprotKB Entry Name | CO1A1_HUMAN,CO1A1_HUMAN |
| Fluid | Urine,Urine |
| M/Z | NA,1742.7158 |
| Charge | NA,NA |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | Nano-LC-MS,MALDI-TOF |
| Peptide Identification technique | MS/MS,MALDI-TOF-MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | 0.01,1 |
| CancerPDF_ID | CancerPDF_ID4773, CancerPDF_ID10820, |
| p-Value | NA,NA |
| Software | "GPM search engine, MASCOT",NA |
| Length | 18,18 |
| Cancer Type | Ovarian cancer,Muscle-invasive bladder cancer |
| Database | IPI 3.71 Human Database ,SwissProt Database |
| Modification | NA,"Oxidation: 2, 5, 11" |
| Number of Patients | 6 Ovarian cancer patients and 6 normal individuals,751 bladder cancer and 127 control |
| Regulation | Uniquely present in case of urine of ovarian cancer patients,Differentially expressed between cancer vs normal samples |
| Validation | NA,Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |
| Primary information |
|---|
| sequence ID | Seq_2048 |
| Peptide sequence | EpGSPGENGApGQMGPRG |
| CancerPDF_ID | CancerPDF_ID3629, |
| PMID | 27026199 |
| Protein Name | Collagen alpha-1(I) chain |
| UniprotKB Entry Name | CO1A1_HUMAN |
| Fluid | Urine |
| fdr | 1725.74 |
| Profiling Technique | "CE-MS, Micro-TOF-MS" |
| Peptide Identification technique | MS-MS |
| Labelled/Label Free | Label Free |
| CancerPDF_ID | CancerPDF_ID3629, |
| p-Value | less than 0.01 |
| Software | Proteome Discoverer 1.2 |
| Length | 18 |
| Cancer Type | Bladder cancer |
| Database | Uniprot Human non-redundant Database |
| Modification | p:Hydroxy-Proline |
| Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
| Regulation | Differentially expressed between recurrence of UBC vs recurrence control |
| Validation | Independent Validation |
| Sensitivity | For testing dataset 88% |
| Specificity | For testing dataset 51% |
| Accuracy | NA |
| Peptide Atlas | NA |
| IEDB | NA |
| Primary information |
|---|
| sequence ID | Seq_2049 |
| Peptide sequence | EpGSpGENGApGQMGPRG |
| CancerPDF_ID | CancerPDF_ID3461, CancerPDF_ID3632, |
| PMID | 27026199,27026199 |
| Protein Name | Collagen alpha-1(I) chain,Collagen alpha-1(I) chain |
| UniprotKB Entry Name | CO1A1_HUMAN,CO1A1_HUMAN |
| Fluid | Urine,Urine |
| M/Z | NA,NA |
| Charge | NA,NA |
| Mass (in Da) | NA,NA |
| fdr | 1741.73,1741.73 |
| Profiling Technique | "CE-MS, Micro-TOF-MS","CE-MS, Micro-TOF-MS" |
| Peptide Identification technique | MS-MS,MS-MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,NA |
| CancerPDF_ID | CancerPDF_ID3461, CancerPDF_ID3632, |
| p-Value | less than 0.05,8.70E-04 |
| Software | Proteome Discoverer 1.2,Proteome Discoverer 1.2 |
| Length | 18,18 |
| Cancer Type | Bladder cancer,Bladder cancer |
| Database | Uniprot Human non-redundant Database,Uniprot Human non-redundant Database |
| Modification | p:Hydroxy-Proline,p:Hydroxy-Proline |
| Number of Patients | 451 for training (341 patients and 110 normal) and 270 for testing(168 primary UBC patients and 102 normal controls);, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
| Regulation | Differentially expressed between primary UBC and normal individual,Differentially expressed between recurrence of UBC vs recurrence control |
| Validation | Independent Validation,Independent Validation |
| Sensitivity | For testing dataset 91%,For testing dataset 88% |
| Specificity | For testing dataset 68%,For testing dataset 51% |
| Accuracy | For testing dataset 76%,NA |
| Peptide Atlas | NA |
| IEDB | |
| Primary information |
|---|
| sequence ID | Seq_2050 |
| Peptide sequence | EpGSpGENGApGQmGPRG |
| CancerPDF_ID | CancerPDF_ID3637, |
| PMID | 27026199 |
| Protein Name | Collagen alpha-1(I) chain |
| UniprotKB Entry Name | CO1A1_HUMAN |
| Fluid | Urine |
| fdr | 1757.73 |
| Profiling Technique | "CE-MS, Micro-TOF-MS" |
| Peptide Identification technique | MS-MS |
| Labelled/Label Free | Label Free |
| CancerPDF_ID | CancerPDF_ID3637, |
| p-Value | less than 0.01 |
| Software | Proteome Discoverer 1.2 |
| Length | 18 |
| Cancer Type | Bladder cancer |
| Database | Uniprot Human non-redundant Database |
| Modification | m: Oxidized-Methionine; p:Hydoxy-Proline |
| Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
| Regulation | Differentially expressed between recurrence of UBC vs recurrence control |
| Validation | Independent Validation |
| Sensitivity | For testing dataset 88% |
| Specificity | For testing dataset 51% |
| Accuracy | NA |
| Peptide Atlas | NA |
| IEDB | NA |